Pancreas cancer. Malignant neoplasm of pancreas
Conditions
Interventions
Intervention 1: The randomized crossover study will be performed on two groups. The first group which will initially receive abraxan: This group will initially receive abraxan (125 mg / m2 of body sur
Treatment - Drugs
The randomized crossover study will be performed on two groups. The first group which will initially receive abraxan: This group will initially receive abraxan (125 mg / m2 of body surface area at the
The second group which will initially receive paclynap: This group will initially receive paclynap (125 mg / m2 of body surface area at the first cycle at days 1, 8 and 15). Then in the next cycle aft
Sponsors
Nano Daru Pajuhan Pardis Co
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: inclusion criteria: with written consent; patients with Local Advanced Pancreatic Cancer. exclusion criteria: patients with hepatic and renal disorders; patients with acute and chronic heart disease; patients with pulmonary and cerebral metastasis; patient with decreased albumin levels of two times of normal; patients with enhanced blood bilirubin of 3 times over.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Paclytaxel serum level. Timepoint: 30 min, one, two, four, six, eight, twelve, twenty four, forty eight hours after injection. Method of measurement: High fluid pressure chromatography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Decrease of tumor. Timepoint: Two months after injection. Method of measurement: Imaging using MRI. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ali Mohammad Alizadeh
Tehran University of Medical Sciences
Outcome results
None listed